With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

"Be mindful about what you're sharing, because once it's online, it's online forever," says Lilly Sabri. The fitness influencer, who has six million followers on YouTube, has urged fans to heed ...

Military veterans planning to see “Warfare” on the big screen will get a special thanks for their service — in the form of discounted tickets. Beginning this weekend, AMC, Cinemark and Regal ...

Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Lilly’s growth. While the aforementioned are the safer bets ...

The triumph of Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S, and related drugs including Zepbound and Mounjaro from Lilly, has set off an all-out push to develop a pill that’s ...

TOKYO -- U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. "We believe ...

Despite being approved in November 2023, Zepbound generated a whopping ... In any event, Eli Lilly’s discount rate of 7.77% is predominately equity-driven (CAPM). Based on these assumptions ...